UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 25, 2016
Stemline Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
001-35619 |
|
45-0522567 |
750 Lexington Avenue
Eleventh Floor
New York, New York 10022
(Address of Principal Executive Offices)
(646) 502-2311
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act.
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
o Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders.
The 2016 annual meeting of stockholders of Stemline Therapeutics, Inc. (Stemline) was held on May 25, 2016. The following matters were voted on by the stockholders: the election of one director, the ratification of the appointment of Ernst & Young LLP as Stemlines independent registered public accounting firm for the year ending December 31, 2016, and the approval of Stemlines 2016 Equity Incentive Plan.
The vote with respect to the nominees for director is set forth below:
Nominee |
|
Total Votes For |
|
Total Votes |
|
Broker Non-Votes |
|
Kenneth Zuerblis |
|
11,258,681 |
|
29,418 |
|
3,420,009 |
|
The vote with respect to the ratification of the appointment of Ernst & Young LLP as Stemlines independent registered public accounting firm for the year ending December 31, 2016 is set forth below:
Total Votes For |
|
Total Votes Against |
|
Abstention |
|
Broker Non-Votes |
|
14,595,593 |
|
110,510 |
|
2,005 |
|
0 |
|
The vote with respect to the approval of Stemlines 2016 Equity Incentive Plan is set forth below:
Total Votes For |
|
Total Votes Against |
|
Abstention |
|
Broker Non-Votes |
|
10,838,144 |
|
430,180 |
|
19,775 |
|
3,420,009 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Stemline Therapeutics, Inc. | |
|
(Registrant) | |
|
| |
|
| |
Date: May 25, 2016 |
| |
|
| |
|
By: |
/s/ Kenneth Hoberman |
|
|
Kenneth Hoberman |
|
|
Chief Operating Officer |